Discontinued — last reported Q3 '23
Danaher Interest Paid decreased by 4.7% to $82.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 21.2%, from $104.00M to $82.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $67.00M | $129.00M | $84.00M | $83.00M | $83.00M | $82.00M | $103.00M | $104.00M | $42.00M | $134.00M | $104.00M | $63.00M | $86.00M | $82.00M |
| QoQ Change | — | +92.5% | -34.9% | -1.2% | +0.0% | -1.2% | +25.6% | +1.0% | -59.6% | +219.0% | -22.4% | -39.4% | +36.5% | -4.7% |
| YoY Change | — | — | — | +23.9% | -35.7% | -2.4% | +24.1% | +25.3% | -48.8% | +30.1% | +0.0% | +50.0% | -35.8% | -21.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.